Results 281 to 290 of about 177,883 (410)

Selective γ-Aminobutyric Acid Type A Receptor Antagonism Reverses Isoflurane Ischemic Neuroprotection [PDF]

, 2006
Hazem E. Elsersy, Javier Mixco, Huaxin Sheng, Robert D. Pearlstein, David S. Warner   +4 more
openalex   +1 more source

Exercise, exerkines, and muscle–brain crosstalk in Parkinson's disease

Neuroprotection, EarlyView.
Abstract Parkinson's disease (PD) is a progressive neurodegenerative disorder with motor and non‐motor symptoms, driven by dopaminergic loss and α‐synuclein accumulation. Beyond neurodegeneration, growing evidence highlights skeletal muscle health as a key determinant of prognosis, with sarcopenia and frailty contributing to greater disability, fall ...
Salomón Páez‐García, Edgar Alvarado, Alejandro Cuevas, Laura Valverde, Eduardo Salinas, Kevin O'Hara‐Veintimilla, María Cruz Rodríguez‐Oroz, Miguel Germán Borda   +7 more
wiley   +1 more source

Intercellular Mitochondrial Transfer as Endogenous Neuroprotection: Mechanisms and Therapeutic Implications in Ischemic Stroke. [PDF]

Transl Stroke Res
Zhang YF, Zhao D, Wei JJ, Liang X, Wang LD, Wang JW, Jiang LB, Chen JY, Zhang YL, Liu Y.   +9 more
europepmc   +1 more source

Increased expression of aromatase after focal cerebral ischemia: Relevance to neuroprotection and functional recovery

Neuroprotection, EarlyView.
Abstract Aim Aromatase is the key enzyme in the biosynthesis of 17β‐estradiol, the most potent estrogen, which has pleiotropic neuroprotective properties. Aromatase levels increase in the brain after stroke, and its gene variants increase susceptibility to stroke. This study aims to determine whether aromatase overexpression improves stroke outcome and
Lindsay Gallagher, Anna F. Dominiczak, Luis M. Garcia‐Segura, Nobuhiro Harada, J. B. Hutchison, James M. Mullin, Delyth Graham, Peter O'Shaughnessy, Hilary Victoria O. Carswell   +8 more
wiley   +1 more source

Neurodegeneration in acute and chronic central nervous system disorders: Novel ideas and approaches

Neuroprotection
Piotr Walczak, Xunming Ji, Shen Li, Johannes Boltze   +3 more
doaj   +1 more source

GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence. [PDF]

J Cent Nerv Syst Dis
Samanidou V, Tsamis K, Ceasovschih A, Koufakis T, Patoulias D, Rizos EC, Rizzo M, Milionis H, Barkas F.   +8 more
europepmc   +1 more source

Post‐recanalization administration of rapamycin improves functional outcome and reduces infarct size in a rat model of ischemic stroke

Neuroprotection, EarlyView.
Experimental design and main findings of the study. Transient middle cerebral artery occlusion was induced for 90 min in rats, followed by intravenous administration of rapamycin or vehicle at the time of recanalization. Functional outcome (Garcia scale and adhesive removal test), magnetic resonance imaging‐based infarct volume assessment, and cerebral
Anna M. Schneider, Yvonne Couch, James Larkin, Alastair M. Buchan, Daniel J. Beard   +4 more
wiley   +1 more source

Propofol Attenuates Brain Ischemic Injury Through the Cannabinoid Type 1 (CB1) Receptor. [PDF]

Cureus
Jia J, Cao M, Zhang Y, Lang J, Xiao R, Peng J, Xu B.   +6 more
europepmc   +1 more source

Nanomedicine and Neuroprotection in Brain Diseases Preface

, 2021
Sharma, Aruna,, Sharma, Hari Shanker,
core  

Bee venom enhances dopaminergic function and behavioral recovery in a murine model of Parkinson's disease

Neuroprotection, EarlyView.
Experimental design and behavioral outcomes of bee venom treatment in a murine model of Parkinson's disease. Mice received an intrastriatal injection of 6‐OHDA into the right hemisphere to induce dopaminergic degeneration. Animals were subsequently treated with l‐DOPA/carbidopa, with or without bee venom (BV) administered intraperitoneally.
Silvia Josefina López‐Pérez, Marco Antonio Noriega‐Ruiz, Alma Karen Lomeli‐Lepe   +2 more
wiley   +1 more source